TNXP
TNXP clinical trials: Tonix Pharmaceuticals Holding Corp.
Every trial on ClinicalTrials.gov where Tonix Pharmaceuticals Holding Corp. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 39
- Trials linked
- 34
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TNXP on the catalyst calendar · TNXP registry changes
- Primary completion Feb 2028Sponsor estimatePhase 2NCT07621237A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)Tonix Pharmaceuticals, Inc. · Major Depressive Episode (MDE)RecruitingTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2024ActualPhase 1NCT07473752A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability...Tonix Pharmaceuticals, Inc. · Phase 1 First-in-human Study Involving Healthy SubjectsCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2022ActualPhase 1NCT07464535A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102...Tonix Pharmaceuticals, Inc. · Healthy Subjects (HS)CompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2026Sponsor estimatePhase 1NCT07413367A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride...Tonix Pharmaceuticals, Inc. · PharmakokineticActive, not recruitingTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2025ActualPhase 2NCT06045793Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)Tonix Pharmaceuticals, Inc. · Cocaine UseTerminatedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 24, 2020ActualPhase 3NCT03841773A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSDTonix Pharmaceuticals, Inc. · PTSDTerminatedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2018ActualPhase 3NCT0311057512-Week Open-Label Extension Study of TNX-102 SL in PTSD PatientsTonix Pharmaceuticals, Inc. · PTSDTerminatedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2016ActualPhase 3NCT02436096A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaTonix Pharmaceuticals, Inc. · FibromyalgiaCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2023ActualPhase 2NCT05679908A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineTonix Pharmaceuticals, Inc. · Chronic MigraineCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 13, 2016ActualPhase 3NCT02829814Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With FibromyalgiaTonix Pharmaceuticals, Inc. · FibromyalgiaTerminatedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2016ActualPhase 3NCT02589275A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia PatientsTonix Pharmaceuticals, Inc. · Primary FibromyalgiaCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 26, 2016ActualPhase 2NCT02421679Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related ConditionsTonix Pharmaceuticals, Inc. · PTSDCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2023ActualPhase 2NCT05686408Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)Tonix Pharmaceuticals, Inc. · DepressionCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2019ActualPhase 3NCT03508700A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSDTonix Pharmaceuticals, Inc. · PTSDCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2023ActualPhase 3NCT05273749A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaTonix Pharmaceuticals, Inc. · FibromyalgiaCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 12, 2023ActualPhase 2NCT05472090A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae...Tonix Pharmaceuticals, Inc. · Post-Acute Sequelae of SARS-CoV-2 (PASC) InfectionCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 17, 2022ActualPhase 1NCT05216510Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide AntigensTonix Pharmaceuticals, Inc. · Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2TerminatedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2016ActualPhase 2NCT02277704Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related ConditionsTonix Pharmaceuticals, Inc. · PTSDCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2018ActualPhase 3NCT03062540Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSDTonix Pharmaceuticals, Inc. · PTSDTerminatedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2021ActualPhase 3NCT04508621A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaTonix Pharmaceuticals, Inc. · FibromyalgiaCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 8, 2022ActualPhase 2NCT05372887Safety and Efficacy Study of TNX-102 SL in Participants With PTSDTonix Pharmaceuticals, Inc. · PTSDWithdrawnTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2020ActualPhase 3NCT04172831A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaTonix Pharmaceuticals, Inc. · FibromyalgiaCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2022ActualPhase 2NCT04996056An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of...Tonix Pharmaceuticals, Inc. · Cocaine IntoxicationWithdrawnTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 24, 2019ActualPhase 1NCT04164719Dose-Proportionality and Food Effect Study of TNX-102 SLTonix Pharmaceuticals, Inc. · Healthy SubjectsCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2011ActualPhase 1NCT01490788A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.Tonix Pharmaceuticals, Inc. · HealthyCompletedTNXPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 14 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner